open access

Vol 61, No 5 (2010)
Congressional papers
Published online: 2010-11-04
Submitted: 2013-02-15
Get Citation

Can procalcitonin be useful for medullary thyroid cancer?

Krzysztof Kaczka, Sławomir Mikosiński, Wojciech Fendler, Anna Jałocha-Kaczka, Lech Pomorski
Endokrynologia Polska 2010;61(5):430-436.

open access

Vol 61, No 5 (2010)
Congressional papers
Published online: 2010-11-04
Submitted: 2013-02-15

Abstract


Introduction: Calcitonin, the best known marker for medullary thyroid cancer (MTC), has several laboratory limitations which limit its use in the routines of non-specialized laboratories. Procalcitonin, the precursor of calcitonin, is free from these drawbacks. The aim of this study was to compare calcitonin and procalcitonin levels in MTC patients with active disease or in remission, and in patients with non-toxic nodular goiter (NTNG).
Material and methods: Forty-three serum samples, obtained from 40 patients (6 MTC active disease patients, 23 MTC patients in remission, and 11 NTNG patients), were tested for calcitonin and procalcitonin levels. The levels of both markers were measured in 2 MTC patients with active disease before and after surgery. One was re-operated due to neck relapse, the other one due to liver metastases.
Results: Both procalcitonin and calcitonin levels were considerably higher in all MTC patients with the active disease. In two re-operated patients, the levels of both markers decreased after surgery but remained above the reference range. In the remission group of MTC patients, 18 had both markers within the reference range, 2 had slightly elevated calcitonin, and 3 patients exhibited both markers slightly increased. In the NTNG group, all but one patient had normal procalcitonin and calcitonin levels. Analysis revealed a significant correlation between procalcitonin and calcitonin levels (r = 0.7383; p < 0.0001).
Conclusions: Procalcitonin has a similar distribution of values as calcitonin and may be used for evaluation of MTC status in some situations when accurate CT estimation is not achievable.
(Pol J Endocrinol 2010; 61 (5): 430-436)

Abstract


Introduction: Calcitonin, the best known marker for medullary thyroid cancer (MTC), has several laboratory limitations which limit its use in the routines of non-specialized laboratories. Procalcitonin, the precursor of calcitonin, is free from these drawbacks. The aim of this study was to compare calcitonin and procalcitonin levels in MTC patients with active disease or in remission, and in patients with non-toxic nodular goiter (NTNG).
Material and methods: Forty-three serum samples, obtained from 40 patients (6 MTC active disease patients, 23 MTC patients in remission, and 11 NTNG patients), were tested for calcitonin and procalcitonin levels. The levels of both markers were measured in 2 MTC patients with active disease before and after surgery. One was re-operated due to neck relapse, the other one due to liver metastases.
Results: Both procalcitonin and calcitonin levels were considerably higher in all MTC patients with the active disease. In two re-operated patients, the levels of both markers decreased after surgery but remained above the reference range. In the remission group of MTC patients, 18 had both markers within the reference range, 2 had slightly elevated calcitonin, and 3 patients exhibited both markers slightly increased. In the NTNG group, all but one patient had normal procalcitonin and calcitonin levels. Analysis revealed a significant correlation between procalcitonin and calcitonin levels (r = 0.7383; p < 0.0001).
Conclusions: Procalcitonin has a similar distribution of values as calcitonin and may be used for evaluation of MTC status in some situations when accurate CT estimation is not achievable.
(Pol J Endocrinol 2010; 61 (5): 430-436)
Get Citation

Keywords

procalcitonin; calcitonin; medullary thyroid cancer; diagnostic marker

About this article
Title

Can procalcitonin be useful for medullary thyroid cancer?

Journal

Endokrynologia Polska

Issue

Vol 61, No 5 (2010)

Pages

430-436

Published online

2010-11-04

Bibliographic record

Endokrynologia Polska 2010;61(5):430-436.

Keywords

procalcitonin
calcitonin
medullary thyroid cancer
diagnostic marker

Authors

Krzysztof Kaczka
Sławomir Mikosiński
Wojciech Fendler
Anna Jałocha-Kaczka
Lech Pomorski

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl